• Reference FLC values are applied globally but were established using serum from mostly White individuals.

  • A κ/λ ratio between 0.686 and 2.10 applies to racially diverse populations and is consistent with known LC disease patterns.

Abstract

Detection of light chain (LC) monoclonal gammopathies (MGs) traditionally relies on serum free LC (FLC) κ, λ, and their ratio (κ/λ) reference ranges based on a mostly White population. We investigated FLC values in a racially diverse population by screening 10 035 individuals for heavy chain MG, identifying 9028 negative cases whose FLC were measured. Participants included 4149 from the PROMISE study (United States, n = 2383; South Africa, n = 1766) and 4879 from the Mass General Brigham Biobank, with 44% self-identifying as Black. Using standard FLC reference ranges, 1074 of 10 035 individuals (10.7%) were diagnosed with LC monoclonal gammopathy of undetermined significance (MGUS), with 99% being κ-restricted. In the United States, 14.8% of Black and 4% of White individuals were diagnosed (P < .01). Among US participants of African (AFR) and European (EUR) genetic ancestry, 14.4% AFR and 2.9% EUR were diagnosed (P < .01). Among South Africans (100% Black), 27.8% were diagnosed using standard ranges. To avoid overdiagnosis, we propose a new κ/λ ratio reference range (0.686 to 2.10) for populations of AFR descent with normal renal function, with standard values for κ and λ being 7.97 to 77.50 mg/L and 6.20 to 49.20 mg/L, respectively. This reduces LC-MGUS overdiagnosis by 91% (10.7% vs 0.97%). Using the new reference, LC-MGUS accounts for 8.8% of MGUS cases, with 74% being κ-restricted, consistent with LC myeloma rates. These findings highlight the importance of basing disease definitions, such as MGUS, on diverse populations. Adopting our proposed FLC reference values would reduce MGUS overdiagnosis among Black individuals, avoiding unnecessary financial, psychological, and medical consequences. This study includes data from NCT03689595.

1.
Rajkumar
SV
,
Dimopoulos
MA
,
Palumbo
A
, et al
.
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
.
Lancet Oncol
.
2014
;
15
(
12
):
e538
-
e548
.
2.
Murray
DL
,
Puig
N
,
Kristinsson
S
, et al
.
Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report
.
Blood Cancer J
.
2021
;
11
(
2
):
24
.
3.
Kyle
RA
,
Gertz
MA
,
Witzig
TE
, et al
.
Review of 1027 patients with newly diagnosed multiple myeloma
.
Mayo Clin Proc
.
2003
;
78
(
1
):
21
-
33
.
4.
Shaheen
SP
,
Levinson
SS
.
Serum free light chain analysis may miss monoclonal light chains that urine immunofixation electrophoreses would detect
.
Clin Chim Acta
.
2009
;
406
(
1-2
):
162
-
166
.
5.
Kyle
RA
.
Sequence of testing for monoclonal gammopathies serum and urine assays
.
Arch Pathol Lab Med
.
1999
;
123
(
2
):
114
-
118
.
6.
Dispenzieri
A
,
Kyle
R
,
Merlini
G
, et al
.
International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
.
Leukemia
.
2009
;
23
(
2
):
215
-
224
.
7.
Katzmann
JA
,
Clark
RJ
,
Abraham
RS
, et al
.
Serum reference intervals and diagnostic ranges for free κ and free λ immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains
.
Clin Chem
.
2002
;
48
(
9
):
1437
-
1444
.
8.
Kumar
S
,
Paiva
B
,
Anderson
KC
, et al
.
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
.
Lancet Oncol
.
2016
;
17
(
8
):
e328
-
e346
.
9.
Tate
JR
,
Gill
D
,
Cobcroft
R
,
Hickman
PE
.
Practical considerations for the measurement of free light chains in serum
.
Clin Chem
.
2003
;
49
(
8
):
1252
-
1257
.
10.
Pattenden
RJ
,
Rogers
SY
,
Wenham
PR
.
Serum free light chains; the need to establish local reference intervals
.
Ann Clin Biochem
.
2007
;
44
(
Pt 6
):
512
-
515
.
11.
Cotten
SW
,
Shajani-Yi
Z
,
Cervinski
MA
,
Voorhees
T
,
Tuchman
SA
,
Korpi-Steiner
N
.
Reference intervals and diagnostic ranges for serum free κ and free λ immunoglobulin light chains vary by instrument platform: implications for classification of patient results in a multi-center study
.
Clin Biochem
.
2018
;
58
:
100
-
107
.
12.
White-Al Habeeb
NMA
,
Earle
T
,
Spencer
M
,
Blasutig
IM
.
Evaluation of the N-latex serum free light chain assay on the Siemens BNII analyzer and agreement with the Binding Site FreeLite assay on the SPAPlus
.
Clin Biochem
.
2018
;
51
:
90
-
96
.
13.
Fleming
CKA
,
Swarttouw
T
,
De Angelino
CMK
,
Jacobs
JFM
,
Russcher
H
.
Method comparison of four clinically available assays for serum free light chain analysis
.
Clin Chem Lab Med
.
2020
;
58
(
1
):
85
-
94
.
14.
Hoedemakers
RMJ
,
Pruijt
JFM
,
Hol
S
, et al
.
Clinical comparison of new monoclonal antibody-based nephelometric assays for free light chain kappa and lambda to polyclonal antibody-based assays and immunofixation electrophoresis
.
Clin Chem Lab Med
.
2011
;
50
(
3
):
489
-
495
.
15.
Hutchison
CA
,
Basnayake
K
,
Cockwell
P
.
Serum free light chain assessment in monoclonal gammopathy and kidney disease
.
Nat Rev Nephrol
.
2009
;
5
(
11
):
621
-
628
.
16.
Hutchison
CA
,
Harding
S
,
Hewins
P
, et al
.
Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease
.
Clin J Am Soc Nephrol
.
2008
;
3
(
6
):
1684
-
1690
.
17.
Long
TE
,
Indridason
OS
,
Palsson
R
, et al
.
Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study
.
Blood Cancer J
.
2022
;
12
(
9
):
133
.
18.
El-Khoury
H
,
Lee
DJ
,
Alberge
J-B
, et al
.
Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study
.
Lancet Haematol
.
2022
;
9
(
5
):
e340
-
e349
.
19.
Lee
DJ
,
El-Khoury
H
,
Tramontano
AC
, et al
.
Mass spectrometry-detected MGUS is associated with obesity and other novel modifiable risk factors in a high-risk population
.
Blood Adv
.
2024
;
8
(
7
):
1737
-
1746
.
20.
Inker
LA
,
Eneanya
ND
,
Coresh
J
, et al
.
New creatinine- and cystatin C–based equations to estimate GFR without race
.
N Engl J Med
.
2021
;
385
(
19
):
1737
-
1749
.
21.
Shlipak
MG
,
Matsushita
K
,
Ärnlöv
J
, et al
.
Cystatin C versus creatinine in determining risk based on kidney function
.
N Engl J Med
.
2013
;
369
(
10
):
932
-
943
.
22.
1000 Genomes Project Consortium
Auton A, Brooks LD, Durbin RM, et al
.
A global reference for human genetic variation
.
Nature
.
2015
;
526
(
7571
):
68
-
74
.
23.
Li
H
,
Handsaker
B
,
Wysoker
A
, et al
.
The sequence alignment/map format and SAMtools
.
Bioinformatics
.
2009
;
25
(
16
):
2078
-
2079
.
24.
Pedregosa
F
,
Michel
V
,
Grisel
O
, et al
.
Scikit-learn: machine learning in Python.
.
J Mach Learn Res
.
2011
;
12
:
2825
-
2830
.
25.
Sakrikar
D
,
Marrot
N
,
North
S
, et al
.
Multi-site verification of the automated EXENT(R) MALDI-TOF-MS system and immunoglobulin isotypes assay for the identification and quantification of monoclonal immunoglobulins. Paper presented at: AACC Annual Scientific Meeting; 28 September 2021; Atlanta, GA
. Accessed 7 October 2021. https://www.abstractsonline.com/pp8/#!/9313/presentation/23.
26.
Horowitz
Gary L
,
Altaie
Sousan
,
Boyd
James C
, et al
. Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline. 3rd ed.
Clinical and Laboratory Standards Institute
;
2010
.
27.
Dispenzieri
A
,
Katzmann
JA
,
Kyle
RA
, et al
.
Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study
.
Lancet
.
2010
;
375
(
9727
):
1721
-
1728
.
28.
Marinac
CR
,
Ghobrial
IM
,
Birmann
BM
,
Soiffer
J
,
Rebbeck
TR
.
Dissecting racial disparities in multiple myeloma
.
Blood Cancer J
.
2020
;
10
(
2
):
19
.
29.
Zemlin
AE
,
Rensburg
MA
,
Ipp
H
,
Germishuys
JJ
,
Erasmus
RT
.
Verification of serum reference intervals for free light chains in a local South African population
.
J Clin Pathol
.
2013
;
66
(
11
):
992
-
995
.
30.
Murray
D
,
Dispenzieri
A
,
Kumar
S
, et al
.
Free light chain assay drift: potential for misdiagnosis?
.
J Appl Lab Med
.
2020
;
5
(
6
):
1411
-
1413
.
31.
Rozenova
K
,
Willrich
M
,
Snyder
M
, et al
.
Kappa free light chain drift prompts the need for a new upper limit of normal free light chain ratio to avoid an epidemic of kappa light chain monoclonal gammopathy of undermined significance
.
J Appl Lab Med
.
2023
;
8
(
4
):
742
-
750
.
32.
Griffiths
M
,
Schneider
RJ
,
Kulasingam
V
.
Serum free light chain and drift: calibrator adjustment needed?
.
J Appl Lab Med
.
2024
;
9
(
2
):
394
-
396
.
33.
Treger
RS
,
Mathias
PC
,
Cowan
AJ
, et al
.
Data analytics improves the diagnostic accuracy of serum free light chain results for detecting monoclonal gammopathy
.
Am J Clin Pathol
.
2024
;
161
(
3
):
216
-
231
.
34.
Van Hoovels
L
,
Vercammen
M
,
Nevejan
L
, et al
.
Serum free light chain analysis: persisting limitations with new kids on the block
.
Clin Chem Lab Med
.
2022
;
60
(
9
):
1440
-
1448
.
35.
Thorsteinsdóttir
S
,
Gíslason
GK
,
Aspelund
T
, et al
.
Prevalence of smoldering multiple myeloma based on nationwide screening
.
Nat Med
.
2023
;
29
(
2
):
467
-
472
.
36.
Lakshman
A
,
Rajkumar
SV
,
Buadi
FK
, et al
.
Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria
.
Blood Cancer J
.
2018
;
8
(
6
):
59
.
37.
Mateos
MV
,
Kumar
S
,
Dimopoulos
MA
, et al
.
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)
.
Blood Cancer J
.
2020
;
10
(
10
):
102
.
38.
Rajkumar
S V
,
Kyle
RA
,
Therneau
TM
, et al
.
Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance
.
Blood
.
2005
;
106
(
3
):
812
-
817
.
39.
Landgren
O
,
Hofmann
JN
,
McShane
CM
, et al
.
Association of immune marker changes with progression of monoclonal gammopathy of undetermined significance to multiple myeloma
.
JAMA Oncol
.
2019
;
5
(
9
):
1293
-
1301
.
40.
Kyle
RA
,
Larson
DR
,
Therneau
TM
, et al
.
Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study
.
Lancet Haematol
.
2014
;
1
(
1
):
e28
-
e36
.
41.
Bomsztyk
J
,
Ravichandran
S
,
Giles
HV
, et al
.
Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis
.
Blood
.
2024
;
143
(
13
):
1259
-
1268
.
42.
Khosla
L
,
Bhat
S
,
Fullington
LA
,
Horlyck-Romanovsky
MF
.
HbA1c performance in African descent populations in the United States with normal glucose tolerance, prediabetes, or diabetes: a scoping review
.
Prev Chronic Dis
.
2021
;
18
:
200365
. 16.
43.
Bagheri
M
,
Chung
CP
,
Dickson
AL
,
Van Driest
SL
,
Borinstein
SC
,
Mosley
JD
.
White blood cell ranges and frequency of neutropenia by Duffy genotype status
.
Blood Adv
.
2023
;
7
(
3
):
406
-
409
.
You do not currently have access to this content.
Sign in via your Institution